在心力衰竭药疗中以患者为中心的结果:随机对照试验的元分析
Kazuhiko Kido1, Masayuki Hashiguchi2, Maya Guglin3
1Department of Clinical Pharmacy, West Virginia University School of Pharmacy, Morgantown, West Virginia, USA.
JACC. Advances
|December 25, 2025
概括
静脉注射铁和GLP1激动剂可以改善心力衰竭患者的生活质量和运动能力. 在慢性心力衰竭中,SGLT2抑制剂可以提高生活质量,但不能提高运动能力.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 针对心力衰竭 (HF) 的指导指导医学治疗可以降低死亡率和发病率.
- 对高频率药物治疗对生活质量 (QOL) 和运动能力的影响仍然不太清楚.
研究的目的:
- 量化HF药疗对以患者为中心的结果的好处,特别是QOL (堪萨斯市心肌病问卷[KCCQ]分数) 和运动能力 (6分钟步行距离 [6MWD]).
- 分析各种HF药物治疗在门诊慢性HF患者的影响.
主要方法:
- 随机对照试验在门诊HF环境中的元分析.
- 干预组包括静脉注射 (IV) 铁,β抑制剂,SGLT2抑制剂,ARNI,MRA, vericiguat, ivabradine以及GLP1或GLP1/GIP激动剂.
- 首要结局是QOL的KCCQ分数和运动能力的6MWD.
主要成果:
- 与安慰剂相比,IV铁,SGLT2抑制剂和GLP1或GLP1/GIP激动剂显著改善了KCCQ得分.
- 与安慰剂相比,GLP1或GLP1/GIP激动剂和IV铁显著改善了6MWD.
- 与安慰剂或活性对照组相比,没有观察到MRA,ARNI, vericiguat或ivabradine在KCCQ或6MWD中的显著差异.
结论:
- 在HF患者中,IV铁和GLP1激动剂或GLP1/GIP激动剂显著改善了QOL和运动能力.
- SGLT2 抑制剂显著改善了 QOL,但没有显著影响运动能力.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
869
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
869
01:30Heart Failure V: Medical Management
195
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
195
01:22Heart Failure Drugs: β-Blockers
724
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
724
01:30Heart Failure VII: Nursing Interventions
389
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
389
01:29Cardiomyopathy V: Interprofessional Care
305
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
305
01:22Heart Failure VI: Adjunct Therapies
228
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
228